BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,616,160 | +15.2% | 652,000 | +14.6% | 1.44% | +31.1% |
| Q2 2023 | $4,005,760 | -12.9% | 569,000 | +3.2% | 1.10% | -20.6% |
| Q1 2023 | $4,599,510 | +59.6% | 551,500 | +119.7% | 1.38% | +69.8% |
| Q4 2022 | $2,881,480 | +12.0% | 251,000 | -66.5% | 0.81% | -2.9% |
| Q3 2020 | $2,573,000 | -27.4% | 749,051 | +0.7% | 0.84% | -18.3% |
| Q2 2020 | $3,545,000 | +270.0% | 744,051 | +55.3% | 1.02% | +155.8% |
| Q1 2020 | $958,000 | -46.0% | 479,051 | -6.8% | 0.40% | -34.3% |
| Q4 2019 | $1,773,000 | +28.0% | 514,051 | +6.3% | 0.61% | +16.9% |
| Q3 2019 | $1,385,000 | -11.0% | 483,388 | +17.6% | 0.52% | -10.9% |
| Q2 2019 | $1,557,000 | -61.6% | 410,888 | -17.6% | 0.58% | -66.6% |
| Q1 2019 | $4,057,000 | +8.2% | 498,415 | +7.3% | 1.75% | -6.1% |
| Q4 2018 | $3,748,000 | -24.7% | 464,415 | -28.8% | 1.86% | -8.8% |
| Q3 2018 | $4,975,000 | +43.6% | 652,086 | +7.8% | 2.04% | +26.0% |
| Q2 2018 | $3,465,000 | -25.5% | 604,652 | -38.0% | 1.62% | -28.3% |
| Q1 2018 | $4,649,000 | -20.7% | 974,652 | -18.3% | 2.26% | -28.3% |
| Q4 2017 | $5,859,000 | -6.3% | 1,193,228 | 0.0% | 3.16% | -18.7% |
| Q3 2017 | $6,253,000 | +90.2% | 1,193,228 | +101.9% | 3.88% | +65.5% |
| Q2 2017 | $3,287,000 | -27.7% | 591,128 | +9.2% | 2.35% | -39.0% |
| Q1 2017 | $4,545,000 | +989.9% | 541,128 | +721.1% | 3.84% | +950.3% |
| Q4 2016 | $417,000 | -1.4% | 65,900 | -56.0% | 0.37% | +0.3% |
| Q1 2016 | $423,000 | -84.0% | 149,642 | -41.5% | 0.36% | -84.5% |
| Q4 2015 | $2,638,000 | -10.5% | 255,642 | -1.2% | 2.35% | -19.6% |
| Q3 2015 | $2,949,000 | -10.9% | 258,642 | +16.7% | 2.93% | +4.5% |
| Q2 2015 | $3,309,000 | +119.9% | 221,656 | +33.0% | 2.80% | +142.1% |
| Q1 2015 | $1,505,000 | -25.8% | 166,656 | 0.0% | 1.16% | -27.9% |
| Q4 2014 | $2,027,000 | +171.4% | 166,656 | +118.1% | 1.60% | +113.0% |
| Q3 2014 | $747,000 | – | 76,400 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |